The primary bottleneck in the gene therapy industry in late 2025 remains the high cost and complexity of large-scale manufacturing. To address this, the sector is moving away from "transient transfection" toward the use of "stable producer cell lines" that can consistently churn out high-quality viral vectors in massive bioreactors. This industrialization of biology is essential for bringing...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
thai 
English
French
Spanish
Portuguese
Italiano
Romaian
Portuguese (Brazil)
china